552 related articles for article (PubMed ID: 18413638)
1. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.
Horwitz EM; Bae K; Hanks GE; Porter A; Grignon DJ; Brereton HD; Venkatesan V; Lawton CA; Rosenthal SA; Sandler HM; Shipley WU
J Clin Oncol; 2008 May; 26(15):2497-504. PubMed ID: 18413638
[TBL] [Abstract][Full Text] [Related]
2. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.
Hanks GE; Pajak TF; Porter A; Grignon D; Brereton H; Venkatesan V; Horwitz EM; Lawton C; Rosenthal SA; Sandler HM; Shipley WU;
J Clin Oncol; 2003 Nov; 21(21):3972-8. PubMed ID: 14581419
[TBL] [Abstract][Full Text] [Related]
3. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
Lawton CAF; Lin X; Hanks GE; Lepor H; Grignon DJ; Brereton HD; Bedi M; Rosenthal SA; Zeitzer KL; Venkatesan VM; Horwitz EM; Pisansky TM; Kim H; Parliament MB; Rabinovitch R; Roach M; Kwok Y; Dignam JJ; Sandler HM
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):296-303. PubMed ID: 28463149
[TBL] [Abstract][Full Text] [Related]
4. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial.
Zapatero A; Guerrero A; Maldonado X; Álvarez A; San-Segundo CG; Rodríguez MÁC; Solé JM; Olivé AP; Casas F; Boladeras A; de Vidales CM; de la Torre MLV; Vara S; Sanz JL; Calvo FA
Lancet Oncol; 2022 May; 23(5):671-681. PubMed ID: 35427469
[TBL] [Abstract][Full Text] [Related]
5. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Pilepich MV; Winter K; John MJ; Mesic JB; Sause W; Rubin P; Lawton C; Machtay M; Grignon D
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1243-52. PubMed ID: 11483335
[TBL] [Abstract][Full Text] [Related]
6. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.
Mirhadi AJ; Zhang Q; Hanks GE; Lepor H; Grignon DJ; Peters CA; Rosenthal SA; Zeitzer K; Radwan JS; Lawton C; Parliament MB; Reznik RS; Sandler HM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):511-515. PubMed ID: 28126300
[TBL] [Abstract][Full Text] [Related]
7. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Roach M; Bae K; Speight J; Wolkov HB; Rubin P; Lee RJ; Lawton C; Valicenti R; Grignon D; Pilepich MV
J Clin Oncol; 2008 Feb; 26(4):585-91. PubMed ID: 18172188
[TBL] [Abstract][Full Text] [Related]
8. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
Warde P; Mason M; Ding K; Kirkbride P; Brundage M; Cowan R; Gospodarowicz M; Sanders K; Kostashuk E; Swanson G; Barber J; Hiltz A; Parmar MK; Sathya J; Anderson J; Hayter C; Hetherington J; Sydes MR; Parulekar W;
Lancet; 2011 Dec; 378(9809):2104-11. PubMed ID: 22056152
[TBL] [Abstract][Full Text] [Related]
9. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.
Chakravarti A; DeSilvio M; Zhang M; Grignon D; Rosenthal S; Asbell SO; Hanks G; Sandler HM; Khor LY; Pollack A; Shipley W;
J Clin Oncol; 2007 Jul; 25(21):3082-9. PubMed ID: 17634487
[TBL] [Abstract][Full Text] [Related]
11. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
Chen RC; Rosenman JG; Hoffman LG; Chiu WK; Wang AZ; Pruthi RS; Wallen EM; Crane JM; Kim WY; Rathmell WK; Godley PA; Whang YE
BJU Int; 2012 Dec; 110(11 Pt B):E721-6. PubMed ID: 23016517
[TBL] [Abstract][Full Text] [Related]
13. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
14. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Mameghan H; Turner S; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Christie D; Spry NA; Tai KH; Wynne C; Duchesne G; Kovacev O; D'Este C;
Lancet Oncol; 2005 Nov; 6(11):841-50. PubMed ID: 16257791
[TBL] [Abstract][Full Text] [Related]
15. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.
Feng FY; Blas K; Olson K; Stenmark M; Sandler H; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):64-71. PubMed ID: 23462420
[TBL] [Abstract][Full Text] [Related]
16. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
[TBL] [Abstract][Full Text] [Related]
17. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
18. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.
Pilepich MV; Krall JM; al-Sarraf M; John MJ; Doggett RL; Sause WT; Lawton CA; Abrams RA; Rotman M; Rubin P
Urology; 1995 Apr; 45(4):616-23. PubMed ID: 7716842
[TBL] [Abstract][Full Text] [Related]
20. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.
Alexander A; Crook J; Jones S; Malone S; Bowen J; Truong P; Pai H; Ludgate C
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):23-30. PubMed ID: 19395187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
